Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Long-term safety and tolerability of tolebrutinib in multiple sclerosis (extension study)
CTR20240417Phase 3Active
- Sponsor
- Sanofi
- Start
- May 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of tolebrutinib in multiple sclerosis (MS), primary progressive multiple sclerosis (PPMS), secondary-progressive multiple sclerosis (SPMS), sponsored by Sanofi. Started May 2024; status: active.
02
Drugs
tolebrutinib
03
Conditions
multiple sclerosis (MS)primary progressive multiple sclerosis (PPMS)secondary-progressive multiple sclerosis (SPMS)
Beyond the preview
Go deeper on CTR20240417.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20240417.